BSE filing, NSE: FERVENTSYN. Summary written from the filing by ALFA Finder's alert engine.
Fervent Synergies Ltd: key numbers
- Share price
- ₹16.50
- Market cap
- ₹82.50 Cr
- Revenue (annual)
- ₹16.35 Cr
- Net profit (annual)
- ₹3.82 Cr
- P/E (TTM)
- 22.7×Sector 19.7×
- Promoter holding
- 74.75%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fervent Synergies Ltd
All →Fervent Synergies Other Announcement
The company has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the quarter ended September 30, 2026.
Fervent Synergies Board Meeting Date
Fervent Synergies Limited has scheduled a board meeting on October 29, 2026. The board will consider and approve unaudited financial results for the September quarter.
Fervent Synergies Annual General Meeting
Fervent Synergies Limited conducted its 17th Annual General Meeting on August 27, 2026. Shareholders approved the audited financial statements and the re-appointment of Director Mr. Karan Vijay Thakkar.
Fervent Synergies Annual Report
Fervent Synergies Ltd has submitted its Annual Report for the financial year 2025-26. This filing includes the notice for the 17th Annual General Meeting.
Fervent Synergies Annual General Meeting
Fervent Synergies Ltd scheduled its 17th Annual General Meeting for September 27, 2026. The register of members will close from August 21 to August 27, 2026.
Fervent Synergies Q1 FY27 Results: Net Profit ₹0.2 Cr, Down 50.0% YoY
Fervent Synergies Ltd reported revenue from operations of ₹0.7 Cr (+0.0% YoY) and net profit of ₹0.2 Cr (-50.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.2 Cr · -50.0% YoY
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.